A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 25 Jun 2024
At a glance
- Drugs Taladegib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Endeavor Pharmaceuticals
- 22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society
- 19 May 2024 According to an Endeavor BioMedicines Media Release, company recently announced the closing of a $132.5 million Series C financing that will support clinical development of ENV-101 in IPF and PPF.
- 19 May 2024 According to an Endeavor BioMedicines Media Release, results were presented for the first time today in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference.